title: Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: beneficial effects on myocardial histology.
abstract: Leukocyte-derived elastase is released following coronary artery occlusion and reperfusion and may contribute to reperfusion-related myocardial injury. Leukocyte infiltration into the reperfused myocardium may also contribute to ischemic injury following reflow. In the present study, we examined the effects of tissue-plasminogen activator (t-PA, 1 mg/kg over 20 minutes) given intravenously with either saline or a leukocyte elastase inhibitor (ICI 200,880, 5 mg/kg) in dogs with electrically-induced coronary artery thrombosis. ICI 200,880 administration increased elastase inhibitory activity without affecting t-PA and plasminogen activator inhibitor (PAI-1) activities. Time to reflow, magnitude of peak coronary blood flow, and duration of reflow were not different in dogs given t-PA with saline or with the elastase inhibitor. However, administration of the elastase inhibitor decreased the histologically-determined leukocyte infiltration and severity of myocardial injury in dogs subjected to coronary artery thrombosis and subsequent thrombolysis. These early observations suggest that elastase release during reperfusion may be an important mediator of anoxia-reoxygenation-mediated tissue injury.
authors.affiliation: Department of Medicine, University of Florida, College of Medicine, Gainesville.
authors.forename: F A
authors.initials: FA
authors.lastname: Nicolini
authors.forename: J L
authors.initials: JL
authors.lastname: Mehta
authors.forename: W W
authors.initials: WW
authors.lastname: Nichols
authors.forename: W H
authors.initials: WH
authors.lastname: Donnelly
authors.forename: R
authors.initials: R
authors.lastname: Luostarinen
authors.forename: T G
authors.initials: TG
authors.lastname: Saldeen
mesh_terms: D000818:Animals; D003328:Coronary Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects*; D007962:Leukocytes / Q000187:drug effects* / Q000201:enzymology; D009206:Myocardium / Q000473:pathology*; D009842:Oligopeptides / Q000627:therapeutic use; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors*; D015849:Plasminogen Inactivators / Q000097:blood; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000627:therapeutic use*
chemical_list: D009842:Oligopeptides; D015849:Plasminogen Inactivators; C069695:ICI 200880; D010196:Pancreatic Elastase; D010959:Tissue Plasminogen Activator